Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (Nasdaq: SMLR) is an innovative medical risk-assessment company focused on developing, manufacturing, and marketing diagnostic and testing products that enhance patient care while bridging the gap between the cost of care and its compensation. Listed on Nasdaq since February 26, 2014, Semler operates primarily in the United States, offering proprietary technology solutions that improve clinical effectiveness and efficiency for healthcare providers, insurance plans, and risk assessment groups.
Semler's flagship product, QuantaFlo®, is a rapid, in-office test for measuring arterial blood flow in the extremities. This four-minute test aids in diagnosing peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is FDA-cleared and is employed by healthcare providers to evaluate patients' risks of mortality and major adverse cardiovascular events (MACE).
Beyond QuantaFlo®, Semler Scientific has made strategic alliances and investments to expand its product portfolio. The company has an exclusive marketing and distribution agreement with Mellitus Health, Inc. for Insulin Insights™, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients. Additionally, Semler holds minority investments in Mellitus, Monarch Medical Technologies LLC (developer of EndoTool® for inpatient glycemic management), and SYNAPS Dx.
In the latest financial results for Q3 2023, Semler reported consistent growth in quarterly revenue and pre-tax net income, predominantly from QuantaFlo® sales. The company continues to focus on expanding its business into heart dysfunction diagnosis.
Semler has also recently adopted Bitcoin as its primary treasury reserve asset, reflecting a strategic move to leverage the digital currency for long-term value and as a hedge against inflation. As of June 6, 2024, the company holds 828 bitcoins, underscoring its commitment to this innovative investment strategy.
More detailed information about Semler Scientific, its products, and investment strategies can be found on their website.
S Santa Clara, Calif.,
Semler Scientific (SMLR) announced a study published in the Journal of Preventive Medicine validating QuantaFlo's role in diagnosing heart dysfunction. The study revealed a significant correlation (p<0.01) between QuantaFlo measurements and cardiac echocardiography, the gold standard in heart failure diagnosis. QuantaFlo offers a quick, non-invasive screening method, potentially transforming heart dysfunction detection in primary care. With 6.2 million heart failure cases in the U.S. and associated costs exceeding $30 billion, the early detection capability may lead to improved patient outcomes. Semler aims to enhance healthcare effectiveness with innovative solutions.
On December 14, 2022, Semler Scientific (SMLR) announced a study published in AJPM Focus, demonstrating the effectiveness of its QuantaFlo® PAD test in screening for peripheral artery disease (PAD) in-home. The study, analyzing data from 192,500 Medicare Advantage beneficiaries, revealed that 27.7% tested positive for PAD. Positive results correlated with significantly higher risk of mortality and cardiovascular events. The findings support the feasibility of a nationwide PAD screening program for older adults and may promote further adoption of QuantaFlo® by healthcare providers.
Semler Scientific (Nasdaq: SMLR) announced a $5.0 million investment in Monarch Medical Technologies via a senior secured convertible note, secured by Monarch's assets. Monarch's EndoTool® Glucose Management System is FDA cleared and used in over 100 U.S. health systems, optimizing inpatient glycemic management. This investment enhances Semler's diabetes management offerings alongside its Insulin Insights™ application. CEO Doug Murphy-Chutorian expressed confidence in Monarch's potential to assist healthcare providers amidst nursing shortages and CMS quality measures.
Semler Scientific (SMLR) reported its Q3 2022 financial results, revealing revenue of $14.0 million, unchanged from Q3 2021. Net income decreased to $3.7 million, or $0.55 per basic share, down from $4.2 million, or $0.61 per basic share a year prior. Cash and equivalents reached $45.5 million, up from $35.9 million in the prior year. Fixed fee software revenues rose 10% to $8.6 million, while variable fee revenues fell 16% to $4.9 million. For 2022, the revenue guidance was adjusted to $55.5 million to $58.0 million.
Semler Scientific, Inc. (Nasdaq: SMLR) has announced it will release its financial results for the third quarter and first nine months of 2022 on November 1, 2022, after U.S. market close. The CEO, Doug Murphy-Chutorian, will lead a conference call at 4:30 pm ET that day, featuring senior executives from the company. Semler Scientific specializes in technology solutions for healthcare, including the FDA-cleared QuantaFlo® test for cardiovascular diseases. They also market Insulin Insights™ and are developing new products to enhance patient care.
Santa Clara, Calif., Aug. 31, 2022 /PRNewswire/ -- Semler Scientific (Nasdaq: SMLR) announced that Renae Cormier, Head of Corporate Communications and Business Strategy, will present at three upcoming investor conferences. The events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12, Lake Street 6th Annual Best Ideas Growth Conference on September 14, and the 7th Annual MicroCap Leadership Summit on September 16. Semler specializes in technology solutions for healthcare, notably with its QuantaFlo® diagnostic tool for cardiovascular diseases.
Semler Scientific (SMLR) reported Q2 2022 revenues of $14.8 million, a 4% increase from Q2 2021. Net income fell by 39% to $4.1 million, or $0.60 per basic share. The company achieved its highest quarterly revenues and cash on hand, totaling $40.0 million. Operating expenses rose to 65% of revenues at $9.6 million, reflecting a 23% increase. For 2022, guidance predicts revenues between $58.0 million and $60.0 million, with an operating expense range of $42.5 million to $44.0 million.
Semler Scientific, Inc. (Nasdaq: SMLR) will report its financial results for the second quarter and first half of 2022 on August 2, 2022, after U.S. market close. CEO Doug Murphy-Chutorian will lead a conference call at 4:30 pm ET the same day. Key executives will also participate in the call, which can be accessed via pre-registration or direct dialing. Semler focuses on technology solutions for healthcare efficiency, with FDA-cleared products like QuantaFlo® aiding in chronic disease diagnosis.
Semler Scientific reported its financial results for Q1 2022. Revenues increased by $0.8 million (6%) to $14.0 million. However, net income fell 31% to $3.4 million, with earnings per share at $0.50 for basic shares. Cash reserves rose significantly to $38.4 million. The company remains committed to profitability and expects Q2 revenues between $14.2 million and $15.2 million.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
What does Semler Scientific, Inc. do?
What is QuantaFlo®?
When did Semler Scientific go public?
What recent achievements has Semler Scientific made?
What is Insulin Insights™?
How is Semler Scientific involved with Bitcoin?
Who are Semler Scientific’s primary customers?
Where is Semler Scientific headquartered?
What other companies is Semler Scientific invested in?
What is the financial outlook for Semler Scientific?
